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SUMMARY
Checkpoint blockade immunotherapies can be extraordinarily effective, but may benefit only the 
minority of patients whose tumors are pre-infiltrated by T cells. Here, using lung adenocarcinoma 
mouse models, including genetic models, we show that autochthonous tumors that lacked T cell 
infiltration and resisted current treatment options could be successfully sensitized to host 
antitumor T cell immunity when using appropriately selected immunogenic drugs (e.g. oxaliplatin 
combined with cyclophosphamide for treatment against tumors expressing oncogenic Kras and 
lacking Trp53). The antitumor response was triggered by direct drug actions on tumor cells, relied 
on innate immune sensing through toll-like receptor 4 signaling, and ultimately depended on 
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CD8+ T cell antitumor immunity. Furthermore, instigating tumor infiltration by T cells sensitized 
tumors to checkpoint inhibition and controlled cancer durably. These findings indicate that the 
proportion of cancers responding to checkpoint therapy can be feasibly and substantially expanded 
by combining checkpoint blockade with immunogenic drugs.
INTRODUCTION
The ability of the immune system to control tumor cells was proposed more than a century 
ago, demonstrated during the last decade, and recently harnessed for therapy (Sharma and 
Allison, 2015; Topalian et al., 2015). A foundational principle of tumor immunology is that 
cancer cells can be eliminated by host cytotoxic CD8+ T cells (Schreiber et al., 2011; 
Gajewski et al., 2013; Schumacher and Schreiber, 2015; Rooney et al., 2015). Accordingly, 
CD8+ T cell infiltration of various solid tumor types has positive prognostic value (Fridman 
et al., 2012), although these cells can be subject to various suppressive mechanisms 
including inhibition by regulatory T (Treg) cells and induced expression of programmed 
death-1 (PD-1) and other inhibitory checkpoint receptors, all limiting the antitumor 
functions of lymphocytes (Sharma and Allison, 2015; Topalian et al., 2015).
Therapies targeting T cell inhibitory checkpoint signaling pathways are redefining cancer 
therapy because clinical trials show unprecedented rates of durable responses in patients 
with common cancer types, including lung adenocarcinoma (Topalian et al., 2015). Lung 
adenocarcinoma was long considered to be nonimmunogenic and is the leading cause of 
cancer incidence and mortality worldwide, with more than one million deaths per year 
(Torre et al., 2015). Yet, only a minority of cancer patients respond to checkpoint inhibition 
and evidence suggests that those patients may preferentially have tumors that have favorable 
mutational landscapes, express the PD-1 ligand (PD-L1) and/or contain pre-existing tumor-
infiltrating CD8+ T cells that are inhibited locally, e.g., by PD-1 engagement (Tumeh et al., 
2014; Sharma and Allison, 2015; Rizvi et al., 2015; Schumacher and Schreiber, 2015; 
Herbst et al., 2014; Topalian et al., 2012; Topalian et al., 2015). In order to define the 
proportion of patients who could ultimately benefit from immunotherapies, it appears 
important to clarify whether strategies can be employed for converting tumor 
microenvironments lacking T cell infiltration to ones displaying antitumor T cell immunity 
and then to determine whether this process sensitizes tumors to checkpoint therapy.
One approach to achieving this goal may involve the induction of immunogenic conditions 
in the tumor microenvironment. For example, some chemotherapeutics and other treatments 
shape clinical outcome by influencing tumor-host interactions to stimulate T cell 
immunosurveillance (Zitvogel et al., 2013; Klug et al., 2013; Shalapour et al., 2015). The 
drugs prescribed today against lung adenocarcinomas only marginally increase survival. 
Despite their low success rate, these drugs deserve re-consideration for several reasons, 
especially when combined with immunotherapy: i) they were originally selected for their 
capacity to prevent human tumor cell growth in vitro and in xenotransplanted 
immunodeficient mouse models without considering the relevance of immune reactions to 
treatment outcomes; ii) they are generally given indiscriminately even though their impact 
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may vary across individuals and tumor microenvironments and iii) improved understanding 
of drug effects in vivo may help identify synergistic treatment options.
To address these knowledge gaps we explored conditional genetic lung adenocarcinoma 
models (with Kras and Trp53 mutations, referred to as KP), in addition to orthotopic KP 
lung tumor models. In the genetic models, cancer cells are derived from somatic cells that 
are transformed in their normal tissue microenvironment and progress to high-grade tumors 
that lack T cell infiltration and resist prescribed chemo- and immunotherapeutic treatments. 
These models can also be used to study autochthonous tumors that express model 
neoantigens, which are important drivers of antitumor T cell immunity (Gubin et al., 2014; 
Rooney et al., 2015) and targets of checkpoint blockade therapy (Schumacher and Schreiber, 
2015). The genetic tumor models we used for this study also avoid the inherent limitations 
of tumor grafts, including sensitivity to numerous chemotherapeutic agents (Olive et al., 
2009).
Here we identified that a combination of clinically-approved chemotherapeutic drugs 
(oxaliplatin-cyclophosphamide; Oxa-Cyc) elicited immunogenic phenotypes on KP tumor 
cells. We also found that Oxa-Cyc treatment fostered CD8+ T cell infiltration into KP 
tumors and delayed cancer progression. Tumor control depended on direct drug actions on 
tumor cells and required both CD8+ T cells and TLR4+ cells. Importantly, the immunogenic 
chemotherapeutics successfully sensitized KP lung adenocarcinomas to immune checkpoint 
blockade. We extended these findings to other tumor types. Consequently, this study 
suggests that anticancer drugs that are rationally selected for triggering tumor 
immunogenicity can be used to make resistant tumors sensitive to checkpoint blockade 
therapy.
RESULTS
KP lung adenocarcinomas resist current treatment options
Kirsten rat sarcoma viral oncogene homolog (KRAS) and tumor suppressor p53 (TP53) 
genes are mutated in ~25% and 50%, respectively, in non-small cell lung cancer (NSCLC) 
patients. Initially, we examined KrasLSL-G12D/+; Trp53flox/flox (hereafter KP) mice that 
express endogenous mutant Kras and deleted Trp53 alleles in lung epithelial cells upon 
administration of adenovirus expressing Cre recombinase (Cortez-Retamozo et al., 2013). 
These mice develop lung adenocarcinomas with both pathophysiological and molecular 
features of the human disease. Evaluation of the lungs of KP tumor-bearing mice revealed 
the presence of CD3+ T cells only within the normal tissue parenchyma and at frequencies 
comparable to those in tumor-free mice; by contrast, all the KP lung adenoma and 
adenocarcinoma nodules lacked CD3+ T cell infiltration (Figures 1A and S1A-C). As 
anticipated for tumors lacking pre-infiltrated T cells, anti-PD-1 monoclonal antibody (mAb) 
treatment failed to delay KP tumor progression (data not shown) and did not increase KP 
mouse survival as defined by the Kaplan-Meier estimator (Figure 1B). Similar results were 
obtained for KP mice on the 129 and C57BL/6 backgrounds (data not shown).
We extended our examination to wild-type mice bearing orthotopic syngeneic KP1.9 lung 
adenocarcinomas harboring Kras and Trp53 mutations. Anti-PD-1 treatment also failed to 
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control tumor progression in this model (Figure 1C). Using a third mouse model, we 
examined whether introducing neoantigens sensitizes KP tumors to immune checkpoint 
therapy. We gave KP mice a Cre-based lentiviral vector containing ovalbumin (OVA) 
peptide sequences to produce KP-OVA mice bearing tumors expressing model OVA 
neoantigens (DuPage et al., 2011). These mice were treated with both anti-PD-1 and anti-
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) mAbs because combined checkpoint 
blockade can increase response rates in cancer patients (Sharma and Allison, 2015; Postow 
et al., 2015; Wolchok et al., 2013). Treatment was initiated on day 133 when lung 
adenocarcinomas were detectable by micro-computed tomography (Figure 1D) and poorly 
infiltrated by CD8+ T cells (DuPage et al., 2011). KP-OVA tumors remained refractory to 
anti-PD-1 and anti- CTLA-4 mAb combination therapy (Figure 1D).
We also assessed the effects of mainstay lung cancer chemotherapeutics in KP mice. 
Besides cisplatin treatment, which only marginally controls KP tumor progression (Oliver et 
al., 2010), we evaluated paclitaxel (Ptax) and carboplatin (Carbo), which are often 
administered in combination because of their synergistic effects on microtubule and DNA 
damage, respectively. We observed that Ptax-Carbo treatment failed both to curb KP tumor 
progression (Figures 1E and S1D) and to extend KP mouse survival (Figure 1F). We also 
assessed tumor infiltration by CD8+ T cells in 76 tumor biopsy sections from NSCLC 
patients who were genotyped for KRAS, TP53 and epidermal growth factor receptor (EGFR) 
mutations. We did not detect differences in CD8+ T cell infiltration based on the KRAS or 
EGFR status of tumors; however, TP53-mutated tumors as well as TP53-KRAS-double 
mutated tumors showed significantly reduced CD8+ T cell infiltration compared to their 
nonmutated counterparts (Figures S1E and S1F). Taken together, these results indicate that 
the KP mouse model is relevant to explore tumors that share important features with their 
human counterparts and, most importantly, resist current immuno- and chemotherapeutic 
interventions.
Selected chemotherapeutics induce KP tumor cell immune phenotypes
Considering that KP tumor nodules lack T cells, we hypothesized that therapeutically 
reversing this phenotype might help control cancer progression. To this end, we initially 
tested diverse chemotherapeutic drug combinations for their ability to induce immunogenic 
phenotypes in various KP tumor cell lines (KP L1-3, L1-5 and L2-9) in vitro. These proof of 
principle studies used high mobility group box 1 (HMGB1) release as a surrogate marker for 
drug-induced tumor cell immunogenicity (Zitvogel et al., 2013) and evaluated Food and 
Drug Administration (FDA)-approved chemotherapeutics to favor clinical translatability. 
We found that the NSCLC chemotherapeutics docetaxel (Dtax) and Carbo, alone or in 
combination, failed to induce HMGB1 release by all KP tumor cell lines tested (Figure 2A). 
Likewise, the anthracycline mitoxantrone (Mtx), which can have immunogenic effects 
(Kroemer et al., 2013), did not trigger HMGB1 release by KP tumor cells, even when 
combined with mafosfamide (Maf) (Figure 2B), which is the active metabolite of 
cyclophosphamide (Cyc) (Schiavoni et al., 2011). However, the oxaliplatin-mafosfamide 
(Oxa-Maf) combination stimulated HMGB1 release by all KP tumor cell lines (Figures 2A 
and 2B). This combination also triggered calreticulin (CRT) exposure by living KP tumor 
cells (Figure 2C), which is an additional marker of cell immunogenicity (Zitvogel et al., 
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2013). Building on these observations, we tested the combined Oxa-Cyc treatment in 
tumorbearing KP mice using well tolerated drug concentrations (Figures S2A and S2B). 
Unlike Ptax-Carbo, Oxa- Cyc treatment significantly increased nuclear HMGB1 staining 
within KP tumor nodules (Figures 2D and S2C), a result that mirrors our in vitro findings. 
These data demonstrate that selected chemotherapeutics can induce immunogenic 
phenotypes in KP lung adenocarcinoma cells both in vitro and in vivo.
Chemotherapeutics selected for their ability to induce immunogenicity in tumors delay KP 
cancer progression
KP mice sacrificed after 3 weeks of Oxa-Cyc treatment showed significantly lower tumor 
burden compared to Ptax-Carbo-treated or untreated mice (Figures 3A and S3A-C). We 
confirmed the ability of Oxa-Cyc treatment to control cancer growth in mice bearing KP1.9 
tumors (Figures S3D-F). As the above experiments used terminal procedures to assess 
tumors at different time points and in different mice, we also used in vivo micro-computed 
tomography to monitor lung tumor volumes over time noninvasively to gain quantitative 
information on lung tumor progression in individual KP mice. This approach confirmed 
overall control of KP tumor growth during Oxa-Cyc treatment duration (Figure 3B). By 
contrast, Ptax-Carbo treatment only showed a limited ability to suppress cancer progression. 
In Oxa-Cyc-treated mice we found that some tumor nodules progressed whereas others 
regressed (Figure 3B) and that tumor cell apoptosis, defined by cleaved caspase 3 staining, 
increased in some but not all tumor nodules (Figure S3G). These data demonstrate the 
possibility of significantly altering KP tumor growth with rationally selected and clinically 
approved chemotherapeutics.
Drug-induced tumor control involves a systemic host response
Having identified Oxa-Cyc as a model of successful treatment against KP tumors, we 
explored how it controlled cancer progression at a mechanistic level in vivo. First, we asked 
whether restricting Oxa-Cyc exposure to KP tumor cells is sufficient to alter cancer 
progression. To address this question, C57BL/6 mice received multiple injections of KP1.9 
cells previously killed in vitro with either Oxa-Maf or Ptax-Carbo (days −8, −4, −2, 5, 12); 
the mice were also challenged with viable KP1.9 cells on day 0. We found that the tumors 
grew more slowly in mice vaccinated with cells killed with Oxa-Maf compared to mice 
vaccinated with tumor cells killed with Ptax-Carbo (Figure 4A). This difference highlighted 
that tumor control is not just a consequence of immunization with dead cells. Of interest, the 
vaccinations had identical effects on tumors injected either ipsior contralaterally, thereby 
further indicating systemic rather than local vaccination-induced effects. Importantly, 
prophylactic vaccination (i.e. Oxa-Maf-killed tumor cells injected on days −8, −4, −2 only) 
was sufficient to reduce both ipsi- and contralateral tumor growth (Figure 4B). 
Consequently, these results indicate that Oxa- Maf-sensitized tumor cells induced systemic 
changes that subsequently reduced cancer progression.
Drug-induced tumor control involves adaptive immunity
Our next step evaluated whether Oxa-Cyc sensitization in vivo promoted an antitumor 
immune response. By collecting single cell suspensions from KP mouse lungs we found 
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increased CD8+ T cell:Treg cell ratios in Oxa-Cyc-treated mice as compared to untreated or 
Ptax-Carbo-treated mice (Figure 4C). The increased CD8+ T cell:Treg cell ratio favors 
CD8+ T cell-mediated cancer immune surveillance and is associated with beneficial 
outcome (Sato et al., 2005; Gao et al., 2007). In further assessing the distribution of T cells 
in KP mouse lungs by immunohistochemistry, we found that Oxa-Cyc treatment instigated 
CD3+ within tumor nodules (Figures 4D and S4A), with some CD3+ cells proliferating 
locally as revealed by Ki67 staining (Figure S4B). The tumor-infiltrating CD3+ T cells, 
which were absent in untreated or Ptax-Carbo-treated mice, were mostly CD8+ and rarely 
CD4+ (Figures 4E and S4C), thereby indicating Oxa-Cyc’s ability to instigate CD8+ T cell 
infiltration into, and proliferation within, KP tumors.
Since Cyc can suppress Tregs (Ghiringhelli et al., 2004; Lutsiak et al., 2005), Oxa-Cyc 
might promote antitumor responses by acting on Tregs directly. However, our data 
suggested that the CD8+ T cell response induced by Oxa-Cyc against KP tumors 
preferentially follows the induction of drug-mediated tumor cell immunogenicity because 
Oxa-Cyc treatment increased CD8+ T cell:Treg cell ratios selectively in lung tumor tissue 
(i.e. not systemically, Figure 4F) and Tregs (as fractions of CD3+ cells) were already absent 
from tumor nodules of untreated mice (Figure S4A). Also, lung CD8+ T cell:Treg cell ratios 
increased more in mice that received both Oxa and Cyc (Figure 4F), a result that was in 
accordance with our in vitro observations that inducing tumor cell immunogenic phenotypes 
required the drug combination (Figures 2A-C).
To test whether therapeutically controlling KP tumor progression needs adaptive immunity, 
we generated Rag2−/− KP mice in the C57BL/6 background (Figures S4D-F). The inability 
of Oxa-Cyc to suppress tumor progression in these mice (Figures 4G and S4G) favors the 
hypothesis that KP tumor control requires CD8+ T cells. Because Rag2−/− KP mice lack 
both T and B cells (Figures S4E and S4F), we also investigated the influence of selective 
CD8+ T cell ablation in immunocompetent (Rag2+/+) KP mice using CD8 depleting mAbs 
(Figure S4H). Oxa-Cyc failed to suppress tumor progression in CD8+ T cell-depleted mice 
(Figure 4H), which indicated that Oxa-Cyc not only instigated tumor infiltration by CD8+ T 
cells but also needed these cells to control cancer growth. Tumor control in KP mice was 
very efficient, especially considering that this mouse model resists all conventional 
treatments and develops tumors that are generally viewed as non-immunogenic.
Drug-induced tumor control involves innate immunity
To delve deeper into drug action mechanisms we next examined whether Oxa-Cyc-induced 
antitumor immunity required variables other than tumor-cell targeting and CD8+ T cells. We 
investigated innate immune cells because they are found in the KP tumor stroma (Cortez-
Retamozo et al., 2012) and may be modulated by drugs to induce tumor control (Broz and 
Krummel, 2015; De Palma and Lewis, 2013). To uncover possible drug-induced changes on 
innate immune cell subsets, we collected lung tissue biopsies of KP tumor-bearing mice 
treated or not with Oxa-Cyc for comparative ex vivo analysis by multi-parameter flow 
cytometry. Furthermore, we isolated both tumor stroma biopsies and tumor-free adjacent 
lung tissue to assess whether drug-induced changes selectively control the immediate tumor 
microenvironment. By operationally dividing CD45+ Lin− myeloid cells into CD11b− and 
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CD11b+ cell subsets, we observed a substantial decrease in the frequency of CD11b− cells in 
both the tumor stroma and adjacent tissue following Oxa-Cyc therapy (Figure 5A). This 
decrease was also observed in Ptax-Carbo-treated mice (data not shown), suggesting that 
this cell loss is insufficient to explain tumor control selectively in Oxa-Cyc-treated mice. In 
marked contrast, Oxa-Cyc treatment significantly and selectively increased the frequency of 
the CD11b+ cell subset within the tumor stroma (Figure 5A). These findings indicate Oxa-
Cyc treatment modulates innate immune system components within the tumor 
microenvironment.
We further analyzed CD11b+ cells, and subsets thereof, and considered toll-like receptor 4 
(TLR4) because it can be involved in innate immune activation and transition toward 
adaptive immunity in the context of druginduced immunogenic cell death (Apetoh et al., 
2007; Kroemer et al., 2013). We found that Oxa-Cyc treatment upregulated TLR4 
selectively in the dendritic cell (DC)/macrophage-like subset, defined as CD11b+ CD11c+ 
Ly- 6G− Ly-6C−. TLR4 upregulation occurred only within the tumor stroma but not in 
tumor-free adjacent tissue (Figure 5B). By comparison, the mean fluorescent intensity (MFI) 
of cell surface TLR4 expression was low or undetectable in CD11b+ CD11c− cells, Ly-6G+/
Ly-6C+ granulocytes and Ly-6C+ monocyte-like cells, both in absence or presence of Oxa-
Cyc treatment (Figure 5B). We also found that CD11b+ CD11c+ cells, in contrast to their 
CD11b+ CD11c− counterpart, upregulated the integrin CD103 (Figure 5C). CD103+ DC-like 
cells are important in regulating antitumor immunity because they have enhanced abilities to 
activate CD8+ T cells compared to CD103− DCs and tumor-associated macrophages (Broz 
et al., 2014; Ruffell et al., 2014; Spranger et al., 2015).
To define whether TLR4+ cells are required for generating drug-induced KP tumor control, 
we examined the impact of Oxa-Cyc treatment on tumor-associated T cell responses in 
Tlr4−/− mice. In contrast to their wild-type counterparts, Tlr4−/− mice failed to increase lung 
CD8+ T cell:Treg cell ratios following Oxa-Cyc treatment (Figure 5D). Furthermore, we 
found that TLR4 deficiency reduced Oxa-Cyc-mediated control of KP tumor progression 
(Figure 5E). These data provide evidence that triggering successful antitumor T cell 
immunity against KP tumors with Oxa-Cyc depends on TLR4, in line with previous findings 
that this receptor can promote DC-mediated CD8+ T cell activation (Apetoh et al., 2007).
Immunogenic chemotherapeutics sensitize lung adenocarcinomas to immune checkpoint 
therapy
With the ability to convert non-T cell infiltrated KP tumors into ones that display antitumor 
T cell immunity, we asked whether this process can be harnessed for sensitizing KP tumors 
to checkpoint blockade therapy. We used the KP-OVA mouse model because it is refractory 
to the anti-PD-1 and anti-CTLA-4 mAb combination therapy (Figure 1D) and allowed us to 
track CD8+ T cells specific for the model antigen OVA257-264. We found that Oxa-Cyc 
treatment in these mice favored or maintained four phenotypes that are potentially 
associated with response to PD-1 checkpoint inhibition, namely: i) increased CD8+ T 
cell:Treg cell ratio in the lung tumor tissue (Figure 6A); ii) presence of tumor-infiltrating 
OVA-specific CD8+ T cells (Figure 6B); iii) PD-1 expression by these cells (Figure 6C) and 
iv) PD-L1 expression by tumor-associated host and/or tumor cells (Figure 6D).
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We conducted a blinded preclinical study in which KP-OVA mice received Oxa-Cyc, anti-
PD-1 + anti-CTLA-4 mAbs or both, with controls left untreated (Figure S5A). Treatments 
began on day 130 after tumor initiation and tumors were monitored noninvasively by high 
resolution micro-computed tomography in all mice at three time points (day 122, day 146, 
and day 193) to quantify changes in tumor burden in vivo. All mice were evaluated ex vivo 
at day 234.
Noninvasive tumor assessment at days 122, 146 and 193 (T0, T1 and T2) revealed that Oxa-
Cyc controlled KP tumors during the first 3 weeks of treatment (T0→T1) when compared to 
untreated mice (p < 0.05) but was unable to control tumors at later time points (T0→T2, p > 
0.05) (Figure 6E). Checkpoint inhibition failed to delay KP tumor progression (T0→T1, p > 
0.05; T0→T2, p > 0.05). By contrast, Oxa-Cyc combined with anti-PD-1 + anti- CTLA-4 
mAb treatment controlled tumor progression at both time points (T0→T1, p < 0.01; T0→T2, p 
< 0.05) (Figures 6E and 6F).
Post mortem evaluation at day 234 (T3) validated the advantage of the combination 
treatment to suppress KP tumors durably (i.e. over 16 weeks; p < 0.001; Figures 6E and 6G). 
The combination treatment was significantly better than either Oxa-Cyc or anti-PD-1 + anti-
CTLA-4 alone (Figures 6E and 6G).
Multiphoton microscopy of explanted lung tissue confirmed successful tumor control in the 
same mice. This approach further revealed the CD8+ T cells’ selective ability to accumulate 
and remain within tumor nodules of Oxa-Cyc-treated KP-OVA mice, whether or not they 
received the immune checkpoint blockers (Figures 6H, S5B and S5C). These data support 
the idea that tumor infiltration by CD8+ T cells is insufficient to durably control cancer 
progression but can generate effective responses to checkpoint blockade treatment.
Additionally, when using the KP1.9 tumor-bearing mouse model, we found that Oxa-Cyc 
treatment significantly increased overall mouse survival when combined with anti-PD-1 + 
anti-CTLA-4 mAbs, whereas anti-PD-1 or anti-CTLA-4 alone did not confer protection 
(Figure S5D). Comparisons of various combination treatments suggested that anti-PD-1 
mAb treatment was mostly responsible for improving Oxa-Cyc treatment efficacy in the 
KP1.9 tumor-bearing mice at least 20 days after initiation of treatment (Figure S5E). Taken 
together these data indicate that rationally selected immunogenic chemotherapeutics can 
sensitize KP lung adenocarcinomas to immune checkpoint therapy.
Immunogenic chemotherapeutics can sensitize other tumors to immune checkpoint 
therapy
Finally, we tested whether other immunogenic chemotherapeutics could sensitize tumors to 
immune checkpoint therapy. We explored MCA205 fibrosarcoma-bearing mice because 
they failed to respond to anti- PD-1 + anti-CTLA-4 mAbs (Figure 7A). We found that 
cisplatin treatment, which does not induce immunogenic cell death, failed to improve 
immune checkpoint blockade treatment (Figure 7A). By contrast, doxorubicin, which 
induces MCA205 immunogenic cell death (Zitvogel et al., 2013), significantly delayed 
tumor progression when combined with anti-PD-1 + anti-CTLA-4 mAb therapy (Figure 
7A).
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We also investigated CT26 colon carcinoma-bearing mice, which did not respond to anti-
CTLA-4 mAb therapy (Figure 7B). Oxa treatment induces immunogenic CT26 tumor cell 
death (Apetoh et al., 2007; Tesniere et al., 2010) and increases CD8+ T cell infiltration at the 
tumor site (Gou et al., 2014). We found that Oxa treatment provided minimal control of 
CT26 tumor progression, similarly to cisplatin, which was used as a control agent (Figure 
7B). Checkpoint blockade therapy with anti-CTLA-4 mAb, either as monotherapy or 
combined with cisplatin, was also largely ineffective. However, the Oxa + anti-CTLA-4 
combination was able to reject CT26 tumors in ~40% of mice analyzed (Figure 7B). These 
results demonstrate that our findings in the KP mouse model can be extended to other tumor 
types; they also indicate that tailoring chemotherapy treatments to a given tumor type may 
be a generalizable approach to sensitize tumors to immune checkpoint therapy.
DISCUSSION
We used genetically-engineered mouse models that closely recapitulate human disease to 
examine whether autochthonous tumors lacking pre-infiltrated T cells can also be sensitized 
therapeutically to induce T cell-mediated control of tumor progression. We investigated lung 
adenocarcinomas carrying common KRAS and/or TP53 mutations because we identified 
these tumors to be inadequately infiltrated by CD8+ T cells in both humans and mice. In 
addition, we found that Kras/Trp53 mutant tumors in mice resist current chemo- and 
immunotherapies even when tumors expressed neoantigens, which are targets of successful 
checkpoint blockade therapy. We report that appropriately selected and clinically approved 
therapeutics can produce CD8+ T cell infiltration in otherwise non-T cell inflamed tumors 
and that this process inhibits cancer progression. Furthermore, the T cell response induced 
by immunogenic chemotherapeutics can be harnessed to sensitize lung adenocarcinomas to 
immune checkpoint therapy. The antitumor response triggered by the immunogenic 
chemotherapeutics depended on: 1) direct drug actions on tumor cells; 2) host CD8+ T cell 
activation; and 3) intact TLR4 signaling.
First, Oxa-Cyc-induced effects on tumor cells alone can trigger a systemic antitumor 
response. Indeed, injecting tumor-bearing mice with KP1.9 tumor cells previously killed by 
Oxa-Maf (but not by Ptax-Carbo) efficiently inhibited tumor progression. Combined with 
our in vitro results, which showed Oxa-Cyc’s ability to directly induce KP tumor cells with 
immunogenic phenotypes, our findings indicate that Oxa-Cyc-mediated effects on tumor 
cells instigate a cascade of events that ultimately lead to tumor control. Whether some 
immunotherapeutics may overcome the limitations of poorly immunogenic 
chemotherapeutics requires further study. Nonetheless, considering the importance of initial 
tumor cell drug targeting, it may be possible to further improve clinical outcomes by 
increasing chemotherapeutic load at the tumor site. This may be achieved by encapsulating 
drugs within nanoparticles (Peer et al., 2007) or targeting the vasculature (Chauhan et al., 
2012).
Second, the Oxa-Cyc-induced antitumor response depends on host CD8+ T cells: the drugs 
failed to control tumor progression in mice lacking these cells (Rag2−/− KP mice as well as 
wild-type KP mice depleted with anti- CD8 mAbs). Another study using a genetic mammary 
cancer model showed that chemotherapeutics can have comparable effects against 
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genetically engineered tumors growing in either Rag-competent or Rag-deficient mice 
(Ciampricotti et al., 2012). These findings suggest that chemotherapy can limit tumor 
progression without CD8+ T cells. Yet, the chemotherapeutics used in the mammary tumor 
models only delayed tumor growth, whereas accumulating evidence shows that potent tumor 
infiltration by CD8+ T cells may be key to durably controlling cancer (Gajewski et al., 2013; 
Tumeh et al., 2014; Spranger et al., 2015). Our study indicates that drug-induced CD8+ T 
cell tumor infiltration can contribute to tumor control in genetic mouse models and be 
harnessed for checkpoint blockade therapy. These findings accord with the observation in a 
mouse model of castrate-resistant prostate cancer that Oxa can induce CD8+ T cell-
dependent tumor eradication (Shalapour et al., 2015).
Third, the drug-induced antitumor T cell response needs intact TLR4 signaling. We 
observed that TLR4 deficiency prevented Oxa-Cyc from increasing CD8+ T cell:Treg cell 
ratios within the tumor bed and from controlling tumor progression. Accordingly, we found 
that Oxa-Cyc makes dying tumor cells release HMGB1, which activates TLR4 directly 
(Apetoh et al., 2007). Also, systemic Oxa-Cyc treatment caused an influx of TLR4+ DC-like 
cells specifically in the tumor stroma. These tumor-infiltrating cells expressed CD103 and 
thus resembled DCs previously identified as critical stimulators of antitumor CD8+ T cell 
immunity (Broz et al., 2014; Ruffell et al., 2014; Spranger et al., 2015). Our results are in 
accordance with previous findings that TLR4 can promote DC tumor antigen cross-
presentation and CD8+ T cell activation following immunogenic tumor cell death (Apetoh et 
al., 2007) and that tumor-infiltrating DCs can be key regulators of antitumor immunity (Broz 
et al., 2014). Although the detailed mechanisms shaping successful immune responses 
against KP tumors require further investigation, the aforementioned findings already provide 
evidence that shaping these immune responses will require a combination of variables 
including tumor cell targeting and both the adaptive and innate arms of the immune system. 
We hypothesize that Oxa-Cyc-induced enrichment of TLR4+ antigen-presenting cells in KP 
tumors precedes and facilitates the local influx of CD8+ T cells. Since TLR4 genotype 
(Casanova et al., 2011) and tumor-associated myeloid cell content (Broz and Krummel, 
2015) can vary across individuals and/or tissues, evaluating these innate immune variables 
may help select treatment options.
Checkpoint blockade therapies have yielded unprecedented clinical benefits against lung and 
other cancers but on their own may preferentially benefit patients whose tumors are pre-
infiltrated by CD8+ T cells (Tumeh et al., 2014; Gajewski et al., 2013). We found that 
therapy-induced T cell infiltration enabled successful treatment with immune checkpoint 
inhibition, further indicating that appropriately selected drugs that transform ‘cold' tumor 
tissues into immunologically ‘hot' T cell-rich environments can be used to sensitize tumors 
to immune checkpoint therapy and improve clinical outcome.
Our results provide a proof-of-principle that chemotherapeutics selected for their ability to 
induce immunogenicity in tumors (e.g. Oxa-Cyc against KP tumors, Doxorubicin against 
MCA205, and Oxa against CT26) provide additive or synergistic benefits when combined 
with immune checkpoint blockers. It will be important to explore whether and when other 
drugs or drug combinations can achieve similar results. For example, it is possible that Oxa 
alone or Ptax-Carbo also sensitize KP tumors to immune checkpoint blockade or synergize 
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with immunotherapy against other cancers. Also, preclinical studies using an ovarian cancer 
graft model indicate that PD-1 blockade can improve Ptax therapy (Lu et al., 2014) and 
ongoing clinical trials are testing the potential of Ptax-Carbo to enhance the efficacy of 
immune checkpoint blocking agents against various cancer types, including NSCLC (Liu et 
al. J Clin Oncol. 2015;33 (suppl; abstr 8030)); Papadimitrakopoulou et al. J Clin Oncol. 
2015;33 (suppl; abstr 8031)).
To achieve tumor sensitization and improved outcomes, we envision two scenarios: 1) re-
evaluating the chemotherapeutics used in combination with checkpoint blockade agents to 
specifically include drugs with the potential to induce immunogenic cell death (e.g., Oxa 
and Cyc as investigated for the KP lung tumor model), and 2) using precision medicine to 
select drugs with the ability to promote tumor cells’ immunogenicity in a given patient. The 
first approach could provide immediate clinical benefit by expanding the proportion of 
cancer patients who respond to current immune checkpoint treatments. The second approach 
involves screening drugs for individual patients and is thus more technically challenging, but 
because it takes into account that different tumor genetic drivers, tissues of origin and tumor 
microenvironments can profoundly modify a given drug’s efficacy, the drug selection 
approach may benefit even more patients. The drug-induced readouts could be expanded to 
study various forms of cell death, including pyroptosis or necroptosis, which could also 
promote antitumor immunity. Regardless of the approach, drugs that are already FDA-
approved could be used to accelerate clinical translation.
EXPERIMENTAL PROCEDURES
Mice
KrasLSL-G12D/+;Trp53flox/flox (KP) mice were used as a conditional mouse model of NSCLC 
(Cortez-Retamozo et al., 2013). Details about all murine strains and tumor models are 
provided in the Supplemental Experimental Procedures. All animal experiments were 
approved by the Massachusetts General Hospital Subcommittee on Research Animal Care, 
except experiments in BALB/c and MCA205-bearing C57BL/6 mice that were approved by 
the Ethical Committee of the Gustave Roussy Cancer Campus (Villejuif, France).
Cell Lines
The lung adenocarcinoma cell line KP1.9 was derived from lung tumors of C57BL/6 KP 
mice and was kindly provided by Dr. A. Zippelius, University Hospital Basel, Switzerland. 
The lung adenocarcinoma cell lines KP L1-3, KP L1-5 and KP L2-9 were derived from 129 
KP mouse lung tumors and all established in our laboratory. Additional information on 
further cell lines and cell culture conditions are detailed in the Supplemental Experimental 
Procedures.
Human Tumor Samples
Sections from paraffin-embedded biopsies of lung resections (n=76) from NSCLC patients 
with known KRAS and EGFR gene mutation status were obtained from the Department of 
Pathology at Massachusetts General Hospital. TP53 and CD8 immunohistochemistry were 
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performed and evaluated blindly based on defined scoring systems as described in the 
Supplemental Experimental Procedures.
Micro-Computed Tomography (µCT) and Magnet Resonance Imaging (MRI)
Tumor burden was evaluated by µCT or MRI in anonymized mice. Details of the imaging 
protocols are provided in the Supplemental Experimental Procedures.
Mouse Histology, Immunohistochemistry (IHC) and Immunofluorescence Microscopy
Histological analysis of tumor burden in mice was done on formaldehyde-fixed and 
paraffin-embedded lung tissues using hematoxylin and eosin (H&E) staining. IHC was done 
on either paraffin-embedded (HMGB1, cleaved caspase-3, Ki67, CD3, CD4) or frozen 
(CD8) tissue sections. Detailed information regarding antibody clones and staining 
procedures are in the Supplemental Experimental Procedures.
Multiphoton Microscopy
Small lung pieces from tumor-bearing KP mice and tumor-free tissue were fixed, stained 
and imaged using an Ultima multiphoton microscope (Prairie Technologies). Images were 
pre-processed in R statistical computing environment using RStudio and stitched/analyzed 
with Fiji software. More information on staining procedures and image processing are 
descripted in the Supplemental Experimental Procedures.
HMGB1 and Calreticulin In Vitro Assays
The KP L1-3, KP L1-5 and KP L2-9 tumor lines were seeded in tissue culture plates before 
treatment with chemotherapeutic drugs for 24 h (Dtax, 30 µM; Carbo, 500 µM; Oxa, 300 
µM; Maf, 16.5, 33, 50 µg/ml; Mtx, 4 µM). For the calreticulin assay, the cells were harvested 
from cell culture plates, fixed and incubated with rabbit anti-calreticulin Ab followed by 
anti-rabbit AlexaFluor 488 conjugated Ab and investigated by flow cytometry (CyAn ADP 
analyzer, Beckman Coulter). Detailed assay conditions are provided in the Supplemental 
Experimental Procedures.
In Vivo Drug Treatments
KP tumor-bearing mice were either left untreated or received chemotherapy 
intraperitoneally (i.p.) once a week for three weeks (Oxa, 2.5 mg/kg; Cyc, 50 mg/kg; Ptax, 
10 mg/kg; Carbo, 10 mg/kg). BALB/c mice bearing CT26 flank tumors and MCA205 flank 
tumor-bearing C57BL/6 mice received one intratumoral chemotherapeutic drug injection 
(Oxa, 1.25 mg/kg; Cisplatin, 0.25 mg/kg; Doxorubicin, 2.9 mg/kg). mAbs specific for PD-1 
(clone 29F.1A12, provided by Dr. G. J. Freeman) and CTLA-4 (clone 9D9, BioXcell) were 
injected i.p.. Details about in vivo experiments including drug treatment conditions and cell 
depletion strategies are provided in the Supplemental Experimental Procedures.
Recovery of Cells from Murine Tissues and Flow Cytometry
Single cell suspensions were prepared from murine lung, spleen and bone marrow and 
investigated by flow cytometry (LSRII, BD Biosciences). Where indicated, equally sized 
pieces of tumor stroma and corresponding tumor-free adjacent tissue were isolated 
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separately from lungs of Oxa-Cyc-treated or untreated tumor-bearing KP mice. Details 
about cell recovery strategies and flow cytometry staining procedures including Ab clones 
and identified cell populations are in the Supplemental Experimental Procedures.
Statistics
Results were expressed as mean±SEM. Statistical tests included one-way ANOVA followed 
by Tukey’s or Dunnett’s multiple comparison test. When applicable, unpaired one-tailed and 
two-tailed Student's t tests using Welch's correction for unequal variances were used. 
Comparison of survival curves was performed with the Log-rank Mantel-Cox test. P values 
of 0.05 or less were considered to denote significance (*P < 0.05; **P < 0.01; ***P < 0.001; 
****P < 0.0001; ns, not significant).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
• Kras/Trp53 mutant tumors lack CD8+ T cells and resist chemo- and 
immunotherapies
• Immunogenic chemotherapy elicits tumor T cell infiltration and controls cancer 
growth
• Tumor control requires CD8+ T cells, TLR4+ cells and drug actions on cancer 
cells
• T cell influx sensitizes tumors to checkpoint inhibition and durably controls 
cancer
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Figure 1. Kras-Trp53-mutated lung adenocarcinomas are inadequately infiltrated by T cells and 
resist current treatment options
A) Immunohistochemistry of CD3+ cells in KP lung tumor tissue on day 66 after tumor 
initiation. (B) Survival of KP mice treated or not with anti-PD-1 (αPD-1) mAbs (n=5-6 mice 
per group). Tumors were induced on day 0 by intratracheal intubation and inhalation (i.t.) of 
an adenovirus expressing Cre recombinase (AdCre). Mice were treated every third or fourth 
day with anti-PD-1 Abs intraperitoneally (i.p.) starting from day 60 to 86. (C) Lung weight 
as proxy for tumor burden (Cortez-Retamozo et al., 2012) measured on day 44 in mice 
bearing orthotopic KP1.9 tumors and treated or not with anti-PD-1 mAbs every third or forth 
day from day 25 to 42 after tumor cell injection (n=9-12 mice per group). (D) Micro-
computed tomography of KP-OVA mice both pre- (day 122) and post-treatment (day 146) 
with no antibody (ø) or with anti-PD-1 and anti-CTLA-4 (αPD-1 + αCTLA-4) mAbs. 
Tumors were induced with a lentiviral vector containing OVA peptide sequences (LucOS) 
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i.t. and mAb treatment was performed every second or third day from day 133 to 145. (E) 
Lung weight (n=4-5 mice per group) and (F) survival (n=11 mice per group) of KP mice 
treated or not with paclitaxel and carboplatin (Ptax-Carbo). Mice were treated once a week 
for three weeks starting on day 63 post i.t. tumor initiation and lungs analyzed three days 
after the last drug injection. For survival studies, Ptax-Carbo was injected i.p. once a week. 
ns, not significant. See also Figure S1.
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Figure 2. Selected drugs induce KP tumor cell immune phenotypes
A) In vitro HMGB1 release by three KP tumor cell lines, generated from lung tissue of 
tumor-bearing KP mice, in response to various chemotherapeutic drug combinations as 
determined by ELISA (n=2-4 replicates). (B) HMGB1 release by tumor cell lines treated 
with Mitoxantrone (4 µM), Oxaliplatin (300 µM) and/or Mafosfamide at different 
concentrations (16.5, 33 or 50 µg/ml) (n=4 replicates). (C) Calreticulin exposure by tumor 
cell lines treated with defined drug combinations measured by flow cytometry (n=6 
replicates). (D) HMGB1 immunohistochemistry (left) and scoring (right) in lung tumor 
nodules (n=39-48) of KP mice untreated (ø) or treated with Ptax-Carbo or Oxa-Cyc (See 
also Figure S2C for comparable images). Scale bars: 100 µm. ****P < 0.0001; ns, not 
significant; CRT, Calreticulin; Carbo, Carboplatin; Cyc, Cyclophosphamide; Dtax, 
Docetaxel; Maf, Mafosfamide; Mtx, Mitoxantrone; Oxa, Oxaliplatin; Ptax, Paclitaxel.
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Figure 3. Drugs selected for their immunogenicity delay KP cancer progression
A) Lung tumor burden identification (left) and quantification (right) by hematoxylin and 
eosin (H&E) staining. Mice were treated with Ptax-Carbo or Oxa-Cyc after establishment of 
lung adenocarcinomas for a duration of 3 weeks. (B) Lung tumor detection by noninvasive 
magnetic resonance imaging both pre- and post-treatment as in (A) (left) and quantification 
of tumor progression, defined as delta tumor volume in mm3, in individual mice over time 
(right, n=5-6 mice per group). Red and green arrowheads show progressing and regressing 
tumor areas, respectively. *P < 0.05; ***P < 0.001; ns, not significant; Tx, treatment; 
Carbo, Carboplatin; Cyc, Cyclophosphamide; Oxa, Oxaliplatin; Ptax, Paclitaxel. See also 
Figure S3.
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Figure 4. Drug-induced tumor control involves adaptive immunity
A and B) Impact of vaccinations with Ptax-Carbo- or Oxa-Maf-killed tumor cells on growth 
of KP1.9 tumors injected on day 0 ipsi- or contralaterally to the vaccination sites. Mice were 
injected with in vitro killed tumor cells on day −8, −4, −2, 5 and 12 (A) or only received 
prophylactic vaccination on day −8, −4 and −2 (B). Tumor burden was analyzed on day 19 
(A) or day 14 (B), respectively (n=6 mice per group). (C) CD8+ T cell:Treg cell ratio in 
lungs of KP mice assessed by flow cytometry at 3 week post-treatment with Ptax-Carbo or 
Oxa-Cyc (n=9-13 mice per group). (D) CD3 immunohistochemistry of representative lung 
tumor sections from KP mice treated as in (C) (see Figure S4A for comparable images). 
Scale bars: 100 µm. (E) CD4 and CD8 immunohistochemistry of lung tumor tissue from 
Oxa-Cyc-treated KP mice (see Figure S4C for comparable images). Scale bars: 100 µm. (F) 
CD8+ T cell:Treg cell ratios assessed by flow cytometry in lung, bone marrow and spleen of 
KP1.9 lung tumor-bearing mice left untreated or that received Ptax-Carbo, Oxa, Cyc or Oxa-
Cyc (n=7-8 mice per group). (G) Lung weight of Rag2−/− KP mice treated or not with Oxa-
Cyc (n=12-14 mice per group). (H) Lung weight of Oxa-Cyc-treated KP mice that received 
CD8 depleting mAbs (αCD8, n=13-15 mice per group). *P < 0.05; **P < 0.01; ****P < 
0.0001; ns, not significant. See also Figure S4.
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Figure 5. Drug-induced tumor control involves innate immunity and TLR4 signaling
A) CD11b− and CD11b+ cells in lung tissue biopsies of KP mice that received Oxa-Cyc or 
were left untreated (n=7-8 mice per group). Lung tissue biopsies of tumor and tumor-free 
adjacent tissues were investigated in parallel. (B) TLR4 mean fluorescence intensity (MFI) 
of CD11b+ cell subsets in tumor and tumor-free lung tissues of Oxa-Cyc treated or untreated 
KP mice (n=7-8 mice per group). (C) CD103 phenotype of CD11b+CD11c− and 
CD11b+CD11c+ cells in tumor stroma of Oxa-Cyc-treated mice (n=7 mice per group). (D 
and E) Lung CD8+ T cell:Treg cell ratio (D) and lung weight (E) of KP1.9 tumor-bearing 
Tlr4+/+ and Tlr4−/− mice treated or not with Oxa-Cyc (n=7-14 mice per group). Lineage 
(Lin) defined as (B220/CD49b/CD90.2/Ter119)+. *P < 0.05; ***P < 0.001; ****P < 
0.0001; ns, not significant; N/A, not applicable.
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Figure 6. Drug-induced tumor infiltration by CD8+ T cells sensitizes lung adenocarcinomas to 
immune checkpoint therapy
A to D) Lung CD8+ T cell:Treg cell ratio (A), percent of OVA-specific CD8+ T cells in 
lungs (B), PD-1 expression by these cells (C) and PD-L1 surface expression by different 
tumor stroma cell populations (D; white histograms are fluorescence minus one (FMO) 
controls) in KP-OVA mice treated or not with Oxa-Cyc (n=2-5 mice per group). (E) 
Experimental scheme of micro-computed tomography imaging time points (d122, d146, 
d193) and ex vivo analysis (d234) of KP-OVA mice treated with Oxa-Cyc and anti-PD-1 + 
anti-CTLA-4 mAbs either alone or in combination (n=5 mice per group). Tumors were 
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induced with a lentiviral vector containing OVA peptide sequences (LucOS). Change in 
tumor volume (defined by micro-computed tomography at d146 = T1 and d193 = T2) and 
tumor area in lung tissues (defined by H&E staining at d234 = T3) in these mice. (F) 
Coronal micro-computed tomography at d122, d146 and d193 of an untreated mouse (left) 
or mouse that received the combination therapy (right). Dotted lines identify tumor nodules 
that progressed (red) or not (green). (G) Lung tumor burden identification by H&E staining 
at d234 in the same mice. (H) CD8+ cell (red) infiltration in KP-OVA tumors (tumor 
contour defined with green dashed-lines, see Figure S5B for comparable images) identified 
by multiphoton microscopy ex vivo at d234 in the same mice. Collagen is shown in blue. *P 
< 0.05; **P < 0.01; ***P < 0.001; ns, not significant. See also Figure S5.
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Figure 7. Immunogenic chemotherapeutics improve immune checkpoint blockade treatment 
against MCA205 fibrosarcoma and CT26 colon carcinoma
A) Tumor size measurement of MCA205 fibrosarcoma-bearing C57BL/6 mice (n=7-8 per 
group) treated with PBS or chemotherapy (Cisplatin or Doxorubicin) together with anti-
PD-1 + anti-CTLA-4 (αPD-1 + αCTLA-4) mAbs or isotype control mAbs. Tumor cells 
were injected on d–8; the chemotherapeutics were given on d0 and the mAbs on d8, 12 and 
16.. (B) Tumor size measurement of CT26 colon carcinoma-bearing BALB/c mice (n=7-8 
per group) treated with PBS or chemotherapy (Cisplatin or Oxaliplatin (Oxa)) together with 
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anti-CTLA-4 or isotype control mAbs. Tumor cells were injected on d–11; the 
chemotherapeutics were given on d0 and the mAbs on d8, 12 and 16. Each line represents an 
individual mouse. *P < 0.05; ns, not significant.
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